%0 Journal Article
%T Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials
%A Wen-cong Li
%A Mao-rong Wang
%A Ling-bo Kong
%A Wei-guang Ren
%A Yu-guo Zhang
%A Yue-min Nan
%J BMC Infectious Diseases
%D 2011
%I BioMed Central
%R 10.1186/1471-2334-11-165
%X All available controlled clinical trials, published from 2004 to 2010, with the following antiviral therapies for CHB patients: PEG-IFN¦Á combined with lamivudine (LAM), PEG-IFN¦Á only, conventional IFN¦Á and LAM, with a course ¡Ý24 weeks, were meta-analysed for HBsAg clearance and seroconversion.Fourteen trials (involving a total of 2,682 patients) were identified, including seven high-quality and seven low-quality studies. The analysis results of the different antiviral therapies on HBsAg clearance or seroconversion were as follows: 1. No significant difference in HBsAg clearance or seroconversion was observed between the combination therapy group and PEG-IFN¦Á monotherapy group [odds ratio (OR) = 1.16, 95% confidence intervals (CI) (0.73-1.85), P = 0.54 and OR = 1.07, 95% CI (0.58-1.97), P = 0.82, respectively]; 2. HBsAg clearance and seroconversion rates in patients with combination therapy were markedly higher than in those with LAM monotherapy [OR = 9.41, 95% CI (1.18-74.94), P = 0.03, and OR = 12.37, 95% CI (1.60-95.44), P = 0.02, respectively]; 3. There was significant difference in HBsAg clearance between the PEG-IFN¦Á group and IFN¦Á monotherapy group [OR = 4.95, 95% CI (1.23-20.00), P = 0.02], but not in seroconversion [OR = 2.44, 95% CI (0.35-17.08), P = 0.37]; 4. PEG-IFN¦Á was superior to LAM in HBsAg seroconversion [OR = 14.59, 95% CI (1.91-111.49), P = 0.01].PEG-IFN¦Á facilitated HBsAg clearance or seroconversion in CHB patients. PEG-IFN¦Á-based therapy was more effective than LAM monotherapy in achieving HBsAg clearance or seroconversion for both HBeAg-positive and HBeAg-negative CHB patients. There was no significant difference in HBsAg clearance or seroconversion between PEG-IFN¦Á/LAM combination therapy and PEG-IFN¦Á monotherapy. PEG-IFN¦Á was obviously superior to conventional IFN¦Á in HBsAg clearance, but not in HBsAg seroconversion. Although PEG-IFN¦Á produced significantly higher rates of HBsAg clearance and seroconversion, the absolute change in the proport
%K hepatitis B
%K HBsAg
%K peginterferon
%K interferon
%K lamivudine
%U http://www.biomedcentral.com/1471-2334/11/165